Clinical Trials

An Important Note:
Clinical trials listed for ITP are a starting point for discussion with a healthcare professional. Be sure you understand all the implications of the proposed treatment by reading the informed consent very carefully and speaking with your doctor before enrolling in a clinical trial.


Doctor with patientWhat are Clinical Trials?

Clinical Trials are controlled patient studies that must be performed before a new drug or treatment is approved by the Food and Drug Administration (FDA) in the United States and similar organizations in other countries. Clinical trials are also completed after a drug or treatment is approved to document the effectiveness of the treatment, or to gain approval to use the drug or therapy for a different disease or age group.

There are three main phases to clinical trials, completed in sequence. A Phase I study tests the safety and side effects of the drug. A Phase II study is initiated to determine the efficacy of the drug, to see if it works as anticipated. And, a Phase III study tests the efficacy of drug or treatment and documents the side effects in a large population of volunteers.


Finding a Clinical Trial

The best way to find the latest information on clinical trials is by visiting ClinicalTrials.gov, a database of privately and publicly funded clinical studies conducted around the world. Pharmaceutical companies and researchers update this site frequently to ensure it contains the most comprehensive and up-to-date clinical trial listings. The database features an easy-to-use search facility and detailed guidance for patients and industry.


Featured Clinical Trials


Ruby-4 Clinical Trial Logo RUBY-4 is a phase 1b/2 clinical study of the safety and potential effectiveness of povetacicept in patients whose ITP is not well controlled with their current medication(s).

  • Povetacicept (pō-və-tak’-i-sept) is designed to block two molecules, BAFF and APRIL, that are important for the function and survival of cells that produce harmful antibodies in patients with ITP.
  • All participants who enroll in RUBY-4 will receive treatment with povetacicept, which will be given as an injection under the skin once a month for 6 months, with potential for a 6-month extension.
  • Povetacicept is provided at no cost, and reimbursement may be available for study-related expenses such as travel.
  • The study is currently enrolling patients in AZ, CA, CO, FL, GA, NJ, NY, TX and in Australia, Canada and Turkey.

To see if you may be a candidate for RUBY-4 participation please go to: www.ruby4clinicalstudy.com


List of Clinical Trials

Please contact PDSA if you find missing or incorrect information regarding any of the clinical trials listed.

 

 

back to top
Charity Navigator
GuideStar Seal
NORD Member Badge
THSNA logo
THSNA Summit 2024
April 3-6th
https://www.thsna.org/2024